Background: Although adenosine monophosphate activated protein kinase (AMPK) plays a
The aim of this study was to investigate the mechanism of AMPK modulation in iodide uptake. Furthermore, we wanted to investigate the potential of the AMPK inhibitor compound C as an enhancer of iodide uptake by thyrocytes.
Methods:
The in vitro and in vivo effects of AMPK modulation on sodium-iodide symporter (NIS) protein levels and iodide uptake were examined in follicular rat thyroid cell-line cells and C57Bl6/J mice. Activation of AMPK by metformin resulted in a strong reduction of iodide uptake (up to sixfold with 5mM metformin after 96 h) and NIS protein levels in vitro, whereas AMPK inhibition by compound C not only stimulated iodide uptake but also enhanced NIS protein levels both in vitro (up to sevenfold with 1 μM compound C after 96 h) and in vivo (1.5-fold after daily injections with 20mg/kg for 4 days). We investigated the regulation of NIS expression by AMPK using a range of promoter constructs consisting of either the NIS promoter or isolated CRE (cAMP response element) and NFwhich are present within the NIS promoter.
Results: Metformin reduced NIS promoter activity (0.6-fold of control), whereas compound C stimulated its activity (3.4-fold) after 4 days. This largely coincides with CRE activation (0.6-and 3.0-fold). These experiments show that AMPK exerts its effects on iodide uptake, at least partly, through the CRE element in the NIS promoter. Furthermore, we have used AMPK-alpha1 knockout mice to determine the long-term effects of AMPK inhibition without chemical compounds. These mice have a less active thyroid, as shown by reduced colloid volume and reduced responsiveness to thyrotropin.
Conclusion:
NIS expression and iodide uptake in thyrocytes can be modulated by metformin and compound C. These compounds exert their effect by modulation of AMPK, which, in turn, regulates the activation of the CRE element in the NIS promoter. Overall, this suggests that the use of AMPK modulating compounds may be useful for the enhancement of iodide uptake by thyrocytes, which could be useful for the treatment of thyroid cancer patients with radioactive iodide.
INTRODUCTION
Adenosine monophosphate-activated protein kinase (AMPK) is an energy-sensing heterotrimeric complex that plays an important role in the energy balance at both the cellular level and the whole body by balancing nutrient supply and demand. It consists of a catalytic -subunit and two regulatory subunits, and , which in turn are expressed as different isoforms ( 1, 2, 1, 2, 1, 2 and 3). Theoretically, this enables the formation of 12 different complexes that may reflect the function of AMPK through different subcellular locations and signalling functions enabling the activation of different pathways (1, 2) . AMPK is known to influence the function of a variety of organs, such as the liver and pancreas (3).
However, reports on the role of AMPK in thyroid function and iodide uptake remain scarce, and much of its function in the thyroid is currently unknown. AMPK can be activated by a range of stimuli, for example hypoxia, starvation, and glucose deprivation, which leads to the activation or inhibition of multiple downstream pathways (4, 5) . Different compounds are known to modulate AMPK activity, such as the AMPK activators metformin and 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR), and the AMPK inhibitor compound C, which is a small-molecule cell-permeable pyrrazolopyrimidine derivative that acts as a reversible ATP competitive inhibitor of AMPK (6) (7) (8) .
In the normally functioning thyroid, iodide accumulation is an essential step in the production of thyroid hormone (TH) and is mediated by the sodium iodide symporter (NIS).
NIS expression itself is driven by several thyroid specific and non-specific regulators (9-11).
Furthermore, iodide uptake is also regulated by the presence or absence of NIS on the cell surface. The shuttling of NIS between cell-surface and cytoplasm provides an extra layer of regulation and is dependent on several factors with an emphasis on thyroid stimulating hormone (TSH) stimulation (11) (12) (13) . The accumulation of iodide by thyrocytes is also exploited in the treatment of thyroid carcinomas by the administration of radioactive iodide-131 ( 131 I; RAI-therapy) and is often the only curative option for recurrent or metastatic disease (14) (15) (16) .
Although both AMPK and the thyroid play a crucial role in energy metabolism (3, 17) , a direct effect of AMPK modulation on thyroid function has only recently been reported in a study by Andrade et al. (18) . In this study, iodide uptake and NIS expression were suppressed after treatment with the AMPK agonist AICAR in PCCL3 follicular thyroid cells, an effect which could be reversed by the AMPK inhibitor Compound C. Furthermore, iodide uptake was reduced in rat thyroid glands after 24 h following a single injection with AICAR.
The aim of our study was to further investigate the role of AMPK in the thyroid using the AMPK activator Metformin and the AMPK inhibitor Compound C, and to provide mechanistic insights into its role in NIS expression and iodide uptake. Our findings give new insight in the subunit composition of AMPK and demonstrate the effects of prolonged modulation of AMPK, an aspect that could be of great importance in the treatment of thyroid cancer, which depends on NIS expression and RAI uptake (14) (15) (16) . We show for the first time that inhibition of AMPK by Compound C in the thyroid results in increased NIS expression, iodide uptake and plasma T4 levels. Thus, inhibition of AMPK or one of its downstream pathways may be a promising treatment strategy to enhance iodide uptake by thyrocytes, which might enhance RAI treatment of thyroid cancer patients. Furthermore, we provide insight in the regulation of NIS expression by AMPK using a range of promoter constructs consisting of either the NIS promoter or isolated CRE (cAMP response element) and NFelements, which are present within the NIS promoter. These experiments show that AMPK exerts its effects on iodide uptake, at least partly, through the CRE element in the NIS promoter.
MATERIALS AND METHODS

Cell culture
The follicular rat thyroid cell-line (FRTL-5) was purchased from Health Protection Agency Culture Collections (Salisbury, UK) (19) . FRTL-5 cells were routinely cultured in Coon's modified Ham's F-12 medium supplemented with 10% charcoal stripped calf serum and a sixhormone (6H) preparation consisting of 5 hormones (5H) (10 g/mL human recombinant insulin (Sigma), 10 ng/mL somatostat transferrin (Sigma) and 10 ng/mL glycyl-L-histidyl-L-lysine acetate (Sigma) supplemented with 100 mU/L bovine TSH (Sigma) (making 6H medium). Cells were maintained in a 5% CO 2 -95% air atmosphere at 37°C with a change of medium every third day, and passed every 7 days. Prior to incubation with AMPK modulating chemicals, monolayers were cultured without calf serum for 8 h.
In vitro treatments
FRTL-5 cells were treated with Metformin or Compound C at a concentration of respectively 2 mM and 5 M for in vitro work.
Iodide uptake in FRTL-5 cells
Iodide uptake was determined as described previously (20, 21) . Briefly, 24 h before the assay, cells were washed and cultured in serum-free medium containing 6H or 5H for TSH-induced iodide uptake in time (19) . After washing twice with Hanks balanced salt solution (HBSS), cells were incubated for 30 min with 500 L of HBSS containing 0.1 Ci of Na 125 unlabeled NaI, with or without 80 M of sodium perchlorate to control for specific uptake.
The radioactive medium was aspirated; cells were washed twice with 1 mL of ice-cold HBSS and accumulated iodide was extracted with 1 mL of 1xSSC+ 0.1% SDS for 30 minutes. All fluids were counted in a -DNA.
Western blot
FRTL-5 cells were lysed directly in Laemmli sample buffer (BioRad, Hercules, CA, USA) and thyroid tissue extracts were prepared in NP buffer using a mini bead beater (BioSpec, Bartlesville, OK, USA) with 1 mm glass beads (Sartorius AG, Goettingen, Germany). 
Animals
For all in vivo experiments with AMPK modulating compounds, 8-week old male C57Bl6/J mice were used. Mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed in conventional cages with a 12:12-h light-dark cycle and free access to food and water. All animal experiments were approved by the institutional ethics committee on animal care and experimentation at Leiden University Medical Center (Leiden, the Netherlands).
of thyroids from AMPK-alpha 1 nockout mice (22) and their littermates were a kind gift from 
In vivo treatments
To evaluate the effect of AMPK modulation on NIS expression in vivo, mice were randomized according to their body weight and divided into 3 groups (n=9). Mice received daily i.p. injections with either Metformin (100 mg/kg), Compound C (20 mg/kg) or vehicle (PBS; control) for 4 days while feeding on a chow diet. I-activity was counted using a -counter.
In vivo iodide uptake
Plasma T4 levels
Plasma T4 levels were measured using the 1100 T4 ELISA kit (Alpha diagnostic, San
Antonio, TX, USA) and TSH levels were measured using the E90463Mu TSH ELISA kit (USCN Life Science Inc., Houston, TX, USA) according to the manufacturer's instructions.
Immunohistochemistry
Mouse thyroids were embedded in paraffin and cut into 4- 
Statistical analyses
Results are expressed as means ± the standard error of means. All data have been analyzed by one-way analysis of variance (ANOVA) followed by a Tukey's post-hoc test with the exception of the results shown in Figure 1 (two-way ANOVA) and Figure 8 (Student's t-test).
All statistical analyses were performed using SPSS v14.0 (SPSS, Inc., Chicago, IL)
RESULTS
Metformin and Compound C influence NIS expression and iodide uptake in vitro
First, we investigated the effect of AMPK activation and inhibition on NIS expression and iodide uptake in vitro by treating follicular thyroid cells (FRTL-5 cells) with Metformin or
Compound C, respectively. The AMPK activator Metformin suppressed TSH-induced iodide uptake in a time-(significant at 16 h) and dose-dependent manner which coincided with a reduction in NIS protein levels ( Fig. 1, 2) . Treatment of Metformin-stimulated FRTL-5 cells with Compound C, an AMPK inhibitor, counteracted the effects of Metformin on iodide uptake and NIS expression (Fig. 3) . Furthermore, Compound C treatment alone was able to increase iodide uptake (significant at 96 h) up to 7-fold after 4 days of treatment ( Fig. 1, 3 ).
This increase in iodide uptake coincided with an increase in NIS protein. Interestingly, as shown in Fig. 3B , in the absence of TSH, remnant NIS protein levels could be repressed even further by Metformin or enhanced by Compound C (Fig. 3B) . 
Regulation of NIS transcription by Metformin and Compound C
The decrease in iodide uptake after Metformin treatment or the increase after Compound C treatment could, at least partially, be explained by de-or increased NIS protein levels (Fig. 2,   3 ). This prompted us to investigate the transcriptional regulation of NIS by Metformin and
Compound C. The regulatory elements in the NIS promoter are located in the NIS upstream enhancer region (NUE), which includes CRE and NFnot inhibit the activation of any of the promoter constructs. However, Compound C was able to increase CRE promoter activity 4.8 fold and slightly activated both rNIS and NF-kb promoter activity by respectively 1.2 and 1.6 fold (Fig 5A) . At day 4, activation of the CRE element coincided with rNIS-promoteractivity after treatment with either Compound C or Metformin (Fig. 5B ). Metformin treatment resulted in a decrease in both rNIS and CRE reporter activity of respectively 1.8 fold and 1.9 fold. Compound C treatment resulted in an increase in rNIS and CRE reporter activity of respectively 3.4 and 3.0 fold. 
Regulation of thyroid function in vivo
To investigate whether modulation of AMPK activity could also influence NIS expression and iodide uptake in thyroid in vivo, we treated mice daily for 4 days. Mice received daily i.p. (Fig 6A-C) . This indicates that the effect of Metformin on NIS protein levels was insufficient to reduce iodide uptake.
FIG. 5.
Activation of reporter constructs after 1 day (A) and 4 days (B) of metformin or compound C treatment. The luciferase-reporter constructs include the rat NIS promoter (fusion of the rNIS proximal promoter -1 to -564 bp and the NUE region -2264bp to -2495 bp, which contains a CRE element and an NFelement) an isolated 3 CRE element and an isolated 3· NF-(lacking TSH) was used as a negative control for CRE as a positive control for NFValues are mean ± SD (n = 6). *p < 0.05 vs. control; **p < 0.01 vs. control; ***p < 0.001 vs. control.
However, after Metformin treatment T4 levels were significantly lower than in Compound C treated animals (Fig. 7A ) but no effects on TSH levels were observed (Fig. 7B) .
A possible explanation for the apparent discrepancy between NIS function and T4 levels could be that Metformin-treated animals were slightly ill (23), or it may be due to a reduction in serum T4 binding proteins which are known to be regulated by metabolic parameters (24) .
In line with our in vitro data, treatment of mice with Compound C resulted in marked upregulation of NIS protein levels (+39%, p<0.05) and 125 I uptake (+55%, p<0.001) in thyroid tissue (Fig 6A, B) . This was also supported by the finding of increased immunohistochemical staining of NIS protein (Fig 6C) . NIS protein levels in thyrocytes were analyzed by Western blot (A) (n = 9/group) and IHC staining (C) (n = 3/group). NIS Western blot data of individual animals were quantified and corrected for GAPDH (A) (inlay pooled fractions) and NIS protein levels were depicted as % of controls ([NIS/GAPDH]/controls · 100%). Iodide -SD (n = 8). **p < 0.05 vs. control; ***p < 0.001 vs. control.
The effects of AMPK-alpha 1 on thyroid function were studied in AMPK alpha 1 knockout mice (Fig. 8) . When compared to controls these mice have an increased colloid diameter (Fig. 8A,B) , raised TSH levels (6-fold) (Fig. 8C ) and decreased T4 levels (0.6-fold) while T3 levels were unaffected (Fig. 8 D, E) .
DISCUSSION
The aim of this study was to investigate the mechanism of AMPK modulation of iodide uptake in thyrocytes. Furthermore, we evaluated the potential of the AMPK inhibitor Compound C as an enhancer of iodide uptake by thyrocytes, which could be of potential benefit in the RAI treatment of thyroid cancer patients. We show that NIS expression and iodide uptake in thyrocytes can be upregulated by Compound C, in vitro and in vivo.
Furthermore, we show that AMPK exerts its effects on iodide uptake, at least partly, through stimulation of the CRE element in the NIS promoter.
In vitro, Metformin was able to increase AMPK activity, which resulted in a strong reduction of iodide uptake and NIS expression, whereas treatment with the AMPK-inhibitory Compound C resulted in a strong increase of iodide uptake and NIS expression. Although these chemical compounds may induce cellular effects which are not directly linked to AMPK repression/or stimulation (25-29) the opposing effects of Metformin and Compound C on iodide uptake and NIS expression point towards an AMPK-related mechanism, which is further supported by a recent study where AICAR was able to inhibit iodide uptake in PCCL3 follicular thyroid cells and rat thyroid glands (18) . In addition, we demonstrate that AMPK in Considering the fact that at this point it is unclear what the effects of AMPK modulation on growth and iodide uptake will be in thyroid tumors, we can only speculate on the clinical impact of AMPK modulation on iodide uptake. However, we think that unraveling the pathways downstream of AMPK leading towards enhanced iodide uptake may enable the differentiation between enhanced iodide uptake and effects on growth.
As the uptake of iodide is the first essential step in the production of TH, we also examined serum T4 levels. There was no difference between control and either treatment but T4 levels were significantly higher in the Compound C treated group when compared to the Metformin treated group (28% increase). Remarkably, TSH levels remained unaffected.
We are aware that long term Metformin treatment (12 months) has been associated with a reduction in TSH levels (33) (34) (35) . These studies describe a lowering of serum TSH levels in hypothyroid and euthyroid diabetic patients with basal TSH levels in the upper normal range without affecting T4 levels. So far no definite explanation has been given for these observations but in our view a possible explanation may be that Metformin sensitizes the thyroid for TSH stimulation after a few months of treatment.
Our study describes the shortterm effects of AMPK modulation by Metformin and Compound C treatments. 4 days of Metformin treatment resulted in decreased iodide uptake and NIS protein levels in follicular thyroid cells, which would suggest a decrease in thyroid function. Therefore short-(4 days) and long-term (1 year) stimulation of AMPK by Metformin seem to have an opposite effect on thyroid function. This is further supported by the addition of new data from AMPK alpha knockout mice, which have increased serum TSH levels without changes in T4 levels (completely opposite to long term AMPK stimulation by Metformin) (33) (34) (35) .
The in vitro decrease in iodide uptake after Metformin treatment or the increase after
Compound C treatment can, at least partially, be explained by decreased or increased NIS protein levels ( Fig. 2 and 3) . We therefore decided to analyze the transcriptional regulation of the NIS promoter. The main regulatory region in the NIS promoter is the NIS upstream enhancer (NUE) region which contains response elements for TTF-1, CRE, Pax8 and NF- coexist, although in our hands, the effects on iodide uptake were not significant after 24 h.
An important factor in NIS regulation is TSH, which is known as the main regulator of NIS at multiple levels. It positively regulates NIS expression at the protein and mRNA level, increases NIS protein half-life, and facilitates translocation to the plasma membrane (11, 12, 20, 37, 38) , making a key regulator of iodide uptake. It activates NIS expression by activating the CRE-like element in the NIS promoter (11) . We have shown that the CRE element may also be involved in the observed effect of AMPK modulation on NIS gene expression because AMPK modulation had a strong effect on CRE activation. Apparently, the downstream effects of TSH activation and AMPK action seem to synergize on the CRE-like element of the NIS promoter. The fact that the CRE element plays a role in both TSH-and AMPK-mediated signalling may also explain the observation that AMPK inhibition with
Compound C increases NIS protein levels even in the absence of TSH. Interestingly, TSH may also be a key player in AMPK modulation by activating its downstream targets cAMP and protein kinase A (PKA) (39) (40) (41) (42) , thus adding an additional pathway to TSH stimulated iodide uptake. PKA activation is able to prevent phosphorylation of the catalytic subunit AMPK-alpha at threonine172 and therefore activation of AMPK in several cell lines including follicular thyroid cell lines (18, (39) (40) (41) (42) . Possible mechanisms include the phosphorylation at serine485/491 or serine173 on AMPK, which blocks threonine172 phosphorylation (39, 40) .
Although activation of the CRE element coincides with rNIS promoter activity 4 days following AMPK modulation, CRE activation by compound C at day 1 exceeds rNIS activation. This implies that additional factors are involved, which perhaps is not surprising as CRE-like site activation in the NUE region of the NIS promoter is closely associated with binding of regulatory elements to flanking regions, especially PAX8 (11) . Once bound, PAX8
can synergize with a range of b-Zip transcription factors at the CRE-like element site to stimulate NUE activity (36) . In contrast to the CRE-like element, activation of the NFelement (9) seems to be of minor importance in the activation of NIS following AMPK modulation.
To conclude, we show that NIS expression and iodide uptake can be modulated by metformin and compound C in thyrocytes. It is likely that these compounds exert their effect by modulation of AMPK, which, in turn, regulates the activation of the CRE element in the NIS promoter. The observed effects on iodide uptake and NIS expression suggest that the use of AMPK-modulating compounds may be useful for the enhancement of iodide uptake by thyrocytes, which could be of potential benefit in the treatment of thyroid cancer patients with RAI.
